Document Classification

Section Type: RESULTS

Text: The rates were significantly lower for the entecavir group vs the lamivudine group for HBV-related hepatitis (0 % vs 13. 3 %, respectively ; difference between groups, 13. 3 % [95 % CI, 4. 7 % to 21. 9 %] ; P =. 003), HBV reactivation (6. 6 % vs 30 % ; difference, 23. 4 % [95 % CI, 10. 2 % to 36. 6 %] ; P =. 001), and chemotherapy disruption (1. 6 % vs 18. 3 % ; difference, 16. 7 % [95 % CI, 6. 4 % to 27. 0 %] ; P =. 002).